Drug intelligence / Profile preview

Mag 9

Development stage: Unknown
Lead developer: FEMA Healthcare
Modality: Small Molecules
Administration: Oral

Overview

Mag 9 is an oral nutraceutical supplement marketed by Fema Health Care, an Indian pharmaceutical company based in Chennai. Formulated as a powder in sachets, it is primarily indicated for women's health, specifically for the management of magnesium deficiency and associated symptoms such as leg cramps during pregnancy. The supplement typically contains magnesium bisglycinate, a chelated form of magnesium known for its high bioavailability and superior gastrointestinal tolerance compared to inorganic magnesium salts. Magnesium is an essential mineral that acts as a cofactor in over 300 enzymatic reactions, supporting neuromuscular function and electrolyte balance, which are critical during the second and third trimesters of pregnancy.

Brand names: Mag 9Mag9Mag-9
Other names: Mag 9 SachetsMag9 SachetsMag-9 Sachets

Beyond the preview

Go deeper on Mag 9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mag 9.

Explore the full profile